1
|
Oliveira SLD, Costa CCD, Aracati MF, Rodrigues LF, Conde G, Moraes ACD, Camplesi AC, Farias THV, Silva IC, Pereira LAM, Belo MADA. Innate immunity response of zafirlukast treated-tilapia during foreign body inflammation. DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY 2024; 153:105112. [PMID: 38092068 DOI: 10.1016/j.dci.2023.105112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/13/2023] [Revised: 12/06/2023] [Accepted: 12/06/2023] [Indexed: 01/10/2024]
Abstract
There is limited knowledge regarding the blockade of cysteinyl leukotriene receptors (CysLTRs) and their effects in teleost fish. The present study investigated the effects of Zafirlukast, antagonist of CysLTR1 receptor, on the foreign body inflammatory reaction in Nile tilapia (Oreochromis niloticus). Zafirlukast-treated tilapia demonstrated a decrease in the formation of multinucleated foreign body giant cells and Langhans cells on the round glass coverslips implanted in the subcutaneous tissue, along with a significant reduction in white blood cell counts and decreased production of reactive oxygen species. There was an increase in serum levels of α2-macroglobulins, as well as a decrease in ceruloplasmin and haptoglobin. Zafirlukast treatment led to a significant decrease in the area of splenic melanomacrophage centers and a reduction in the presence of lipofuscin. These findings highlight the potential anti-inflammatory effects of zafirlukast treatment in tilapia and indicate its action on CysLTR1 receptor, modulating the innate immune response of tilapia during the foreign body reaction. The comprehension of chronic inflammation mechanisms in fish has become increasingly relevant, especially concerning the utilization of biomaterials for vaccine and drug delivery.
Collapse
Affiliation(s)
| | | | | | | | - Gabriel Conde
- Department of Preventive Veterinary Medicine, São Paulo State University (UNESP), Brazil
| | | | | | | | - Ives Charlie Silva
- Chemistry Institute, IQ -UNESP (São Paulo State University), Araraquara, SP, Brazil
| | | | - Marco Antonio de Andrade Belo
- Department of Preventive Veterinary Medicine, São Paulo State University (UNESP), Brazil; Brazil University - (UB), Descalvado, SP, Brazil.
| |
Collapse
|
2
|
Aracati MF, Luporini de Oliveira S, Rodrigues LF, Carlino da Costa C, Cristina de Moraes A, da Rosa Prado EJ, Fernandes DC, Vaz Farias TH, Eto SF, Charlie-Silva I, de Andrade Belo MA. Antagonism of cysteinyl leukotriene receptors by zafirlukast modulated acute inflammatory reaction in tilapia, Oreochromis niloticus. FISH & SHELLFISH IMMUNOLOGY 2022; 130:323-331. [PMID: 36122633 DOI: 10.1016/j.fsi.2022.09.030] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/11/2022] [Revised: 09/07/2022] [Accepted: 09/13/2022] [Indexed: 06/15/2023]
Abstract
To identify activation pathways and effector mechanisms of innate immunity in fish has become relevant for the sanitary management of intensive fish farming. However, little is known about the blocking of cysteinyl leukotrienes receptors (CysLTRs) and their effects in teleost fish. Our study evaluated the anti-inflammatory effect of 250 and 500 μg zafirlukast (antagonist of CysLTRs)/kg b.w., administered orally in the diet, during acute inflammatory reaction induced by Aeromonas hydrophila bacterins in Oreochromis niloticus. 80 tilapia were distributed in 10 aquariums (100L of water each, n = 8) to constitute three treatments: Control (inoculated with A. hydrophila bacterin and untreated); Treated with 250 μg or 500 μg of zafirlukast/kg b.w. and inoculated. To be evaluated in three periods: 6, 24 and 48 h post-inoculation (HPI), totaling nine aquariums. A tenth group was sampled without any stimulus to constitute reference values (Physiological standards). Tilapia treated with zafirlukast demonstrated dose-response effect in the decrease of accumulated inflammatory cells, strongly influenced by granulocytes and macrophages. Zafirlukast treated-tilapia showed decrease in blood leukocyte counts (mainly neutrophils, and monocytes) and reactive oxygen species production. Treatment with zafirlukast resulted in down-regulation of ceruloplasmin, complement 3, alpha2-macroglobulin, transferrin and apolipoprotein A1, as well as up-regulation of haptoglobin. Our study provided convincing results in the pathophysiology of tilapia inflammatory reaction, considering that treatment with zafirlukast, antagonist of cysteinyl leukotriene receptors, resulted in a dose-response effect by suppressing the dynamics between leukocytes in the bloodstream and cell accumulation in the inflamed focus, as well as modulated the leukocyte oxidative burst and the acute phase protein response.
Collapse
Affiliation(s)
- Mayumi Fernanda Aracati
- Department of Preventive Veterinary Medicine, São Paulo State University (UNESP), Jaboticabal, SP, Brazil
| | | | - Leticia Franchin Rodrigues
- Department of Preventive Veterinary Medicine, São Paulo State University (UNESP), Jaboticabal, SP, Brazil
| | - Camila Carlino da Costa
- Department of Preventive Veterinary Medicine, São Paulo State University (UNESP), Jaboticabal, SP, Brazil
| | | | - Ed Johnny da Rosa Prado
- Department of Preventive Veterinary Medicine, São Paulo State University (UNESP), Jaboticabal, SP, Brazil
| | - Dayanne Carla Fernandes
- Department of Preventive Veterinary Medicine, São Paulo State University (UNESP), Jaboticabal, SP, Brazil
| | | | - Silas Fernandes Eto
- Department of Preventive Veterinary Medicine, São Paulo State University (UNESP), Jaboticabal, SP, Brazil
| | - Ives Charlie-Silva
- Deparment of Pharmacology, University of São Paulo-ICB/USP, São Paulo, SP, Brazil
| | - Marco Antonio de Andrade Belo
- Department of Preventive Veterinary Medicine, São Paulo State University (UNESP), Jaboticabal, SP, Brazil; Laboratory of Animal Pharmacology and Toxicology, Brazil University - (UB), Descalvado, SP, Brazil.
| |
Collapse
|
3
|
Hussenbocus YAAM, Jin Z, Pan W, Liu L, Wu M, Hu H, Ding X, Wei H, Zou Y, Qian X, Wang M, Wu J, Tao J, Tan J, Da Z, Zhang M, Li J, Feng X, Sun L. Low dosage use of cyclophosphamide improves the survival of patients with systemic lupus erythematosus. Clin Rheumatol 2022; 41:2043-2052. [PMID: 35230560 DOI: 10.1007/s10067-022-06117-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2021] [Revised: 12/28/2021] [Accepted: 02/22/2022] [Indexed: 11/29/2022]
Abstract
OBJECTIVE To investigate the effect of cyclophosphamide (CYC) on organ involvement and SLE patients' overall and cause-specific mortality. METHODS Information about CYC prescription was taken from the Jiangsu Lupus database, which was set up to collect medical records from SLE patients since their first admission during 1999-2009 in Jiangsu province, China. Follow-up studies were carried out in 2010 and 2015 to check the survival status of the patients. Cox regression models were used to estimate the hazard ratio (HR) and 95% CI. Kaplan-Meier model was used to assess the effect of CYC on mortality between organ involvement and non-involvement. RESULTS There were 221 deaths observed out of 2446 SLE patients. CYC users decreased overall mortality of SLE (8.4%) with adjusted HR (95% CI) of 0.74 (0.56-0.97), as compared to non-users. A decrease in overall mortality of SLE was found in the low dosage (< 600 mg) of CYC users, with adjusted HR (95% CI) of 0.54 (0.36-0.81). The protection of CYC on mortality of SLE was further observed in subgroups, such as female; SLEDAI score ≥ 15 group; and those with neuropsychiatric, renal, and hematological involvements, and low serum C3. In addition, CYC could eliminate the differences in mortality between organ involvement and non-involvement, including renal, neuropsychiatric, cardiopulmonary, gastrointestinal, and hematological involvement, but not for mucocutaneous and musculoskeletal involvement. CONCLUSION Low dosage use of CYC decreased the risk of overall mortality of SLE. CYC might improve the survival of SLE patients with renal, neuropsychiatric, cardiopulmonary, gastrointestinal, and hematological involvements. Key Points • Cyclophosphamide decreases overall mortality of SLE patients. • Decreased mortality is mainly observed from low dosage use of cyclophosphamide. • Cyclophosphamide improves the survival of SLE patients when major systems such as renal, neuropsychiatric, cardiopulmonary, gastrointestinal, and hematological are involved.
Collapse
Affiliation(s)
| | - Ziyi Jin
- Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, 321 Zhongshan Road, Nanjing, 210008, China.
| | - Wenyou Pan
- Department of Rheumatology, Huai'an First People's Hospital, Huai'an, China
| | - Lin Liu
- Department of Rheumatology, Xuzhou Central Hospital, Xuzhou, China
| | - Min Wu
- Department of Rheumatology, the Third Affiliated Hospital of Soochow University, Changzhou, China
| | - Huaixia Hu
- Department of Rheumatology, Lianyungang Second People's Hospital, Lianyungang, China
| | - Xiang Ding
- Department of Rheumatology, Lianyungang First People's Hospital, Lianyungang, China
| | - Hua Wei
- Department of Rheumatology, Northern Jiangsu People's Hospital, Yangzhou, China
| | - Yaohong Zou
- Department of Rheumatology, Wuxi People's Hospital, Wuxi, China
| | - Xian Qian
- Department of Rheumatology, Jiangsu Province Hospital of TCM, Nanjing, China
| | - Meimei Wang
- Department of Rheumatology, Southeast University Zhongda Hospital, Nanjing, China
| | - Jian Wu
- Department of Rheumatology, the First Affiliated Hospital of Soochow University, Suzhou, China
| | - Juan Tao
- Department of Rheumatology, Wuxi TCM Hospital, Wuxi, China
| | - Jun Tan
- Department of Rheumatology, Zhenjiang First People's Hospital, Zhenjiang, China
| | - Zhanyun Da
- Department of Rheumatology, Affiliated Hospital of Nantong University, Nantong, China
| | - Miaojia Zhang
- Department of Rheumatology, Jiangsu Province Hospital, Nanjing, China
| | - Jing Li
- Department of Rheumatology, Affiliated Hospital of Jiangsu University, Jiangsu, China
| | - Xuebing Feng
- Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, 321 Zhongshan Road, Nanjing, 210008, China
| | - Lingyun Sun
- Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, China. .,Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, 321 Zhongshan Road, Nanjing, 210008, China.
| |
Collapse
|
4
|
de Andrade Belo MA, Charlie-Silva I. Teleost Fish as an Experimental Model for Vaccine Development. Methods Mol Biol 2022; 2411:175-194. [PMID: 34816405 DOI: 10.1007/978-1-0716-1888-2_10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
Advances in vaccine development depend on animal models to test innovative therapies. Recent studies have reported the successful introduction of teleost fish as a new vertebrate model in scientific research, with emphasis on the species Danio rerio (zebrafish). This chapter aims to give an overview of important aspects related to the immune system of fish, as well as the current progress of the successful use of these animals in studies for the development of vaccines, assisting in the determination of efficacy and clinical safety. Among the advantages of using fish for the development of vaccines and immunomodulatory drugs, it is worth highlighting the reproductive capacity of these animals resulting in a high number of individuals belonging to the same spawning, transparent embryos, low cost of breeding and high genetic similarity that favor translational responses to vertebrate organisms like humans.
Collapse
Affiliation(s)
| | - Ives Charlie-Silva
- Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil
| |
Collapse
|
5
|
Belo MAA, Oliveira MF, Oliveira SL, Aracati MF, Rodrigues LF, Costa CC, Conde G, Gomes JMM, Prata MNL, Barra A, Valverde TM, de Melo DC, Eto SF, Fernandes DC, Romero MGMC, Corrêa Júnior JD, Silva JO, Barros ALB, Perez AC, Charlie-Silva I. Zebrafish as a model to study inflammation: A tool for drug discovery. Biomed Pharmacother 2021; 144:112310. [PMID: 34678720 DOI: 10.1016/j.biopha.2021.112310] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2021] [Revised: 09/20/2021] [Accepted: 10/05/2021] [Indexed: 12/18/2022] Open
Abstract
This study aims to demonstrate the applicability and importance of zebrafish (Danio rerio) model to study acute and chronic inflammatory responses induced by different stimuli: carrageenan phlogogen (nonimmune); acute infection by bacteria (immune); foreign body reaction (chronic inflammation by round glass coverslip implantation); reaction induced by xenotransplantation. In addition to the advantages of presenting low breeding cost, high prolificity, transparent embryos, high number of individuals belonging to the same spawning and high genetic similarity that favor translational responses to vertebrate organisms like humans, zebrafish proved to be an excellent tool, allowing the evaluation of edema formation, accumulation of inflammatory cells in the exudate, mediators, signaling pathways, gene expression and production of specific proteins. Our studies demonstrated the versatility of fish models to investigate the inflammatory response and its pathophysiology, essential for the successful development of studies to discover innovative pharmacological strategies.
Collapse
Affiliation(s)
- Marco A A Belo
- Laboratory of Animal Pharmacology and Toxicology, Brazil University (UB), Descalvado, Brazil; Department of Preventive Veterinary Medicine, São Paulo State University (UNESP), Jaboticabal, Brazil
| | - Melque F Oliveira
- Laboratory of Animal Pharmacology and Toxicology, Brazil University (UB), Descalvado, Brazil
| | - Susana L Oliveira
- Department of Preventive Veterinary Medicine, São Paulo State University (UNESP), Jaboticabal, Brazil
| | - Mayumi F Aracati
- Department of Preventive Veterinary Medicine, São Paulo State University (UNESP), Jaboticabal, Brazil
| | - Letícia F Rodrigues
- Department of Preventive Veterinary Medicine, São Paulo State University (UNESP), Jaboticabal, Brazil
| | - Camila C Costa
- Department of Preventive Veterinary Medicine, São Paulo State University (UNESP), Jaboticabal, Brazil
| | - Gabriel Conde
- Department of Preventive Veterinary Medicine, São Paulo State University (UNESP), Jaboticabal, Brazil
| | - Juliana M M Gomes
- Department of Morphology, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil
| | - Mariana N L Prata
- Department of Physiology and Pharmacology, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil
| | - Ayslan Barra
- Department of Physiology and Pharmacology, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil
| | - Thalita M Valverde
- Department of Morphology, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil; Department of Biochemistry and Immunology, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil
| | - Daniela C de Melo
- Department of zootechnics at the Veterinary School, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil
| | - Silas F Eto
- Postgraduate Program in Health Sciences - PROCISA, Federal University of Roraima, Brazil
| | | | - Marina G M C Romero
- Department of Physiology and Pharmacology, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil
| | - José D Corrêa Júnior
- Department of Morphology, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil
| | - Juliana O Silva
- Department of Clinical and Toxicological Analyses, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil
| | - Andre L B Barros
- Department of Clinical and Toxicological Analyses, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil
| | - Andrea C Perez
- Department of Physiology and Pharmacology, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil
| | - Ives Charlie-Silva
- Department of Pharmacology, University of São Paulo (ICB-USP), São Paulo, Brazil.
| |
Collapse
|